Trastuzumab deruxtecan and tucatinib (in combination with trastuzumab and capecitabine), in particular, have been shown to be effective in treating HER2‐positive breast cancer brain metastases [7, 8, 9]. Here, ERBB2 is linked to breast carcinoma.